TP53 and cancer: In summary, FM leads to the downregulation of xCT and GPX4, confirming that FM induces ferroptosis by inhibiting the p53/xCT/GPX4 pathway, which modulates oxidative stress and ferroptosis, targets tumor metabolic vulnerabilities, and serves as a broad-spectrum therapeutic target for cancers (Figure 8).